Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Nīmes
With
Institut de Recherches en Biothérapie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has been correctly informed.
The patient must have given their informed and signed consent.
The patient must be insured or beneficiary of a health insurance plan.
The patient is at least (≥)18 years old.
The patient has experienced a CIS, has currently a RRMS or progressive MS with:
* Less than 10 years of disease duration;
* With or without DMD;
* EDSS score 0 - 7.0.
You may not be if
The patient is in an exclusion period determined by a previous study.
The patient is under judicial protection.
The patient refuses to sign the consent.
It is impossible to correctly inform the patient (Inability to understand the study, language problem).
The patient is pregnant or breast-feeding.
Patient has a bilateral optic neuritis or other significant ophthalmological antecedent.
Patient with MRI contra-indications.
patient has a contraindication to gadolinium injection
The patient has bilateral optic neuritis or other significant ophthalmological antecedent
Patient is having a relapse or has had a relapse in the last 3 months
The patient has a severe psychiatric illness
The patient has severe chronic alcoholism
Clareo Health | Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
